Dr. Eckstein, President, comes to SR One from TVM Capital where he was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVMs Boston life sciences practice where he focused on earlier-stage investments. He is currently a Director of Thrasos Therapeutics, Palleon Pharma, Decibel Therapeutics, Gladius Pharmaceuticals and ZappaRx. He also was a member of the Board of Directors for Alios BioScience, CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an Advisor to Sirtris Pharmaceuticals.
Jens was the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company. Prior to joining TVM Capital, Jens led drug discovery programs at Enanta Pharmaceuticals, Inc. and Mitotix, Inc.
He is the author of multiple scientific publications and holds several issued patents. Jens is an Advisor to the Alzheimer Research Forum (ARF), a Board Member of BioHealth Innovation (BHI) and a Kauffman Fellow.
Jens is the father of three teenagers and lives with his family in Cambridge, Massachusetts.
Dr. Eckstein will be speaking at World Anti-Microbial Resistance Congress USA 2016 about ‘Private funding for antibacterial drug development’. This session will answer the following questions:
- What is the current landscape of VC funding for antibacterial development?
- How to balance risk vs. profitability?
- How has the GAIN Act incentivized private funding?
To hear from Dr. Jens Eckstein and more industry experts, attend World Anti-Microbial Resistance Congress USA 2016, held September 8-9 in Washington, DC.